Yemaachi Biotechnology

yemaachi.com →

-77%

est. 2Y upside i

HealthcareSeed

Diversifying precision cancer diagnostics and treatments

Rank

#824

Sector

Biotechnology

Est. Liquidity

~5Y

Data Quality

Data: Low

Yemaachi Biotechnology presents a moderate upside opportunity for a job seeker, driven by its unique and strong competitive moat in African genomics and strategic partnerships with industry giants like Roche and Illumina.

Last updated: February 25, 2026

Bull (25%)+300%

Yemaachi successfully expands the African Cancer Atlas with additional pharma partners, leading to significant biomarker discoveries and early-stage drug development collaborations. This drives a Series B round at a $240M valuation, a 4x increase from current, within two years.

Base (45%)+100%

Yemaachi continues to grow its diagnostic services and data partnerships, leveraging the African Cancer Atlas. The company secures a strong Series A extension or Series B round at a $120M valuation, doubling its current valuation, as it progresses towards clinical validation and further data generation.

Bear (30%)-80%

Despite partnerships, the high capital intensity and long development cycles of biotech lead to slower-than-expected progress in drug development and data monetization. This results in a challenging follow-on funding round, potentially a flat or down round at a $12M valuation, significantly impacting common stock value.

Est. time to liquidity~5.0 years

Preference Stack Risk

moderate

Investors hold approximately $6.125M in liquidation preferences, representing about 10.2% of the estimated $60M current valuation.

Dilution Risk

high

As an early-stage biotech, Yemaachi will require multiple significant funding rounds (Series A, B, C, etc.) to reach commercialization, leading to substantial future dilution for current equity holders.

Secondary Liquidity

none

Given the company's early stage and private status, there is currently no active secondary market for employee equity.

Other — 1 role

View all 1 open roles at Yemaachi Biotechnology →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Yemaachi Biotechnology's data — designed to show you've done your homework.

  • 1

    “How is Yemaachi planning to balance the long-term, capital-intensive drug discovery efforts with the more immediate revenue generation from diagnostic services and data collaborations?”

  • 2

    “Given the ambitious goal of the African Cancer Atlas, what are the key milestones and challenges anticipated in scaling data collection and ensuring data quality and ethical governance across multiple African countries?”

  • 3

    “With the recent bridge round and ongoing need for capital, what is the company's strategy for its next major funding round (Series A/B), and how does the current valuation reflect the progress made with partnerships like Roche and Illumina?”

Community

Valuation Sentiment

Our model estimates -77% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.